SCHEDULE: EcoR1 Capital Discloses 9% Stake in Fulcrum Therapeutics

EcoR1 Capital, LLC and Oleg Nodelman have reported a 9% beneficial ownership stake in Fulcrum Therapeutics, Inc. via a Schedule 13G filing.

Summary

• EcoR1 Capital, LLC, its affiliate EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman have filed a Schedule 13G indicating a combined beneficial ownership of 6,000,000 shares of Fulcrum Therapeutics, Inc. common stock.
• The reported stake represents 9.0% of the company's outstanding common stock, based on 66,633,321 shares outstanding as of April 20, 2026.
• The reporting persons share voting and dispositive power over the 6,000,000 shares.
• The filing confirms the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while it does not change the company's fundamentals, the presence of a significant, specialized institutional investor often provides a floor for the stock price and suggests external validation of the company's pipeline.

Positives

• Significant institutional investment from a specialized healthcare-focused investment firm, signaling confidence in the company's long-term prospects.

Negatives

• None identified in this regulatory disclosure.

Risks

• The investment is subject to general market risks associated with biotechnology equity holdings.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest, which is standard but highlights the nature of fund-based holdings.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's operations, but confirms the holding is for investment purposes in the ordinary course of business.

Industry Context

StockSavvy.ai notes that EcoR1 Capital is a well-known life sciences investment firm. Their accumulation of a 9% stake in a biotech firm like Fulcrum Therapeutics is typical of institutional 'smart money' positioning in the sector, often preceding or following clinical milestones or strategic shifts.

Comparison to Industry Standards

• The filing follows standard SEC requirements for institutional investors crossing the 5% ownership threshold.
• The disclosure of shared voting and dispositive power is consistent with standard practices for investment advisers and their managed funds.

Stakeholder Impact

• Shareholders may view the increased institutional stake as a sign of confidence in the company's long-term value.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.

Key Dates

Recommendation

The filing indicates institutional confidence but does not provide new operational data. Investors should hold and monitor for further activity from EcoR1 or the company's upcoming clinical results.

Keywords

Fulcrum Therapeutics, EcoR1 Capital, Schedule 13G, Biotechnology, Institutional Ownership, Oleg Nodelman, Common Stock